Raising Perkin Elmer's Fair Value Estimate on Strong Trends and Long-Term Outlook

With myriad acquisitions and divestitures in the past decade, PerkinElmer has been in a constant state of evolution. While its medical imaging divestiture and structural changes historically constrained margins, we are confident that the firm’s renewed strategic focus on improving its diagnostic product mix and life sciences business will sustain returns over cost of capital in the long run. PerkinElmer's competitive positioning has certainly shifted for the better, and with several attractive avenues of growth within reach, particularly in emerging markets, we believe the firm will produce tangible benefits for shareholders for the next several years.